Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis

Abstract

The main cause of discontinuation of anti-TNFα is therapeutic failure in both diseases. Etanercept and infliximab have the best survival rates in RA and AS, respectively.

Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry

“…Our findings with CT-P13 are consistent with previous studies of infliximab (28)(29)(30)(31)(32). In a Korean single-centre study involving patients with AS and RA, 79% of patients with AS treated with a first TNF inhibitor remained on treatment at 2 years; median drug retention time with infliximab RP did not differ from etanercept or adalimumab (30).…”

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study

“…The effectiveness of TNF inhibitors and other biologics might be lost over time despite a good initial response (secondary treatment inefficacy). The development of anti-drug antibodies is a notable reason for secondary failure [ 18 ], and loss of efficacy represents the foremost reason for TNF inhibitor treatment discontinuation [ 19 ]. Secondary loss of efficacy has not been documented with small molecule JAK inhibitors and the present study provides evidence that loss of treatment response may not be a challenge with JAK inhibitors, including baricitinib.…”

Effectiveness of biologics in patients with rheumatoid arthritis – a single-center experience

“…if remission is not achieved within six months of therapy with at least two dmards, the use of a biologic or biosimilar drug is indicated. literature data indicate that, despite the improved remission rates with the use of biologics and/or biosimilars, ineffectiveness of the drug develops in up to 60% of the patients (8,9).…”

“…ako se ne postigne remisija uz primjenu najmanje dvaju dmard-a tijekom šest mjeseci od uvođenja lijekova, indicirana je primjena jednog od dostupnih bioloških ili biosličnih lijekova. literaturni podatci upućuju na to da se unatoč boljem postizanju remisije primjenom bioloških i/ili biosličnih lijekova i u do 60% bolesnika razvije jedan od oblika neučinkovitosti na lijek (8,9). cilj rada je bio istražiti učinkovitost liječenja biološkim i biosličnim lijekovima u grupi bolesnika s ra.…”